» Articles » PMID: 27730104

Relation Between Initial Treatment Strategy in Stable Coronary Artery Disease and 1-year Costs in Ontario: a Population-based Cohort Study

Overview
Journal CMAJ Open
Specialty General Medicine
Date 2016 Oct 13
PMID 27730104
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cardiovascular disease is costly, and annual expenditures are projected to increase. Our objective was to examine the variation in patient-level costs and identify drivers of cost in patients with stable coronary artery disease.

Methods: In this retrospective cohort study using administrative databases in Ontario, Canada, we identified all patients with stable coronary artery disease after index angiography between Oct. 1, 2008, and Sept. 30, 2011. We excluded patients with a myocardial infarction within 90 days before the index, with normal coronaries, or with mild coronary disease. We categorized hospitals into low, medium or high revascularization ratio centres. The primary outcome was cumulative 1-year health care costs. A hierarchical generalized linear model identified patient, physician and hospital characteristics associated with patient costs, with 2 main covariates of interest: treatment allocation (medical v. percutaneous coronary intervention v. coronary artery bypass grafting) and hospital revascularization ratio.

Results: A total of 183 630 angiography procedures were performed in Ontario during the study period. The final cohort included 39 126 patients with stable coronary artery disease, of which 15 138 received medical treatment and 23 988 received revascularization. The mean 1-year cost was $24 026 (interquartile range $8235-$30 511). The mean costs for medical management and revascularization were $18 069 and $27 786, respectively. The strongest predictor of costs was revascularization (percutaneous coronary intervention: cost ratio 1.27, 95% CI [confidence interval] 1.24-1.31; coronary artery bypass grafting: cost ratio 2.62, 95% CI 2.53-2.71). Hospital revascularization ratio did not significantly affect costs. There was no significant interaction between treatment and revascularization ratio.

Interpretation: Most health care costs were due to acute care hospital admissions, and costs were higher for patients undergoing revascularization than medical therapy. This study suggests that treatment decision has a substantial impact on health care resources.

Citing Articles

Cost-Effectiveness of Colchicine for Recurrent Cardiovascular Events.

Boczar K, Beanlands R, Wells G, Coyle D CJC Open. 2023; 5(5):348-356.

PMID: 37377518 PMC: 10290950. DOI: 10.1016/j.cjco.2023.02.005.


Cost-Effectiveness of Canakinumab From a Canadian Perspective for Recurrent Cardiovascular Events.

Boczar K, Beanlands R, Wells G, Coyle D CJC Open. 2022; 4(5):441-448.

PMID: 35607490 PMC: 9123368. DOI: 10.1016/j.cjco.2022.01.003.


Association of Clinical and Economic Outcomes With Permanent Pacemaker Implantation After Transcatheter Aortic Valve Replacement.

Aljabbary T, Qiu F, Masih S, Fang J, Elbaz-Greener G, Austin P JAMA Netw Open. 2019; 1(1):e180088.

PMID: 30646053 PMC: 6324315. DOI: 10.1001/jamanetworkopen.2018.0088.


Economic Impact of Subsequent Depression in Patients With a New Diagnosis of Stable Angina: A Population-Based Study.

Szpakowski N, Qiu F, Masih S, Kurdyak P, Wijeysundera H J Am Heart Assoc. 2017; 6(10).

PMID: 29021276 PMC: 5721880. DOI: 10.1161/JAHA.117.006911.

References
1.
Wijeysundera H, Wang X, Tomlinson G, Ko D, Krahn M . Techniques for estimating health care costs with censored data: an overview for the health services researcher. Clinicoecon Outcomes Res. 2012; 4:145-55. PMC: 3377439. DOI: 10.2147/CEOR.S31552. View

2.
Bennell M, Qiu F, Kingsbury K, Austin P, Wijeysundera H . Determinants of variations in initial treatment strategies for stable ischemic heart disease. CMAJ. 2015; 187(10):E317-E325. PMC: 4500728. DOI: 10.1503/cmaj.141372. View

3.
Anderson J, Heidenreich P, Barnett P, Creager M, Fonarow G, Gibbons R . ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63(21):2304-22. DOI: 10.1016/j.jacc.2014.03.016. View

4.
Stewart S, Murphy N, Murphy N, Walker A, McGuire A, McMurray J . The current cost of angina pectoris to the National Health Service in the UK. Heart. 2003; 89(8):848-53. PMC: 1767798. DOI: 10.1136/heart.89.8.848. View

5.
Simoons M, Windecker S . Controversies in cardiovascular medicine: Chronic stable coronary artery disease: drugs vs. revascularization. Eur Heart J. 2010; 31(5):530-41. DOI: 10.1093/eurheartj/ehp605. View